Synexus, a Manchester-based multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients, has got its first contract to conduct mild cognitive impairment (MCI) study.
Earlier in November 2010, the company has signed an agreement with Roger Bullock, for the development of more effective clinical trials for this field.
Currently, Synexus is in discussions with a number of sponsors with a view to undertake further MCI trials.
Synexus CEO Christophe Berthoux said they have seen an increase in interest from sponsors who are investing significant sums of money into research for new treatments for MCI.
"Sponsors want to partner with clinical trials companies that actually deliver the number of patients needed to get their study underway, within the time frame agreed at the outset," Berthoux said.